


Quantitative FDG-PET/CT

Accelerating development of new therapies and improving assessment of response



PET-CT: A Proud History of Innovation



What's next? Quantitative PET to Characterize Disease Hallmarks


Drivers

- Clinical research, Clinical trials, and Drug discovery
- New molecular diagnostic agents
- Assessing individual response to therapy
- SUVs are now routinely reported, and are asked for, by referring physicians

Response to therapy of liver met GIST

volume

Biomarkers To Quantify Hallmarks of Cancer



- New molecular diagnostic agents
- New uses for existing agents

Quantitation Improves Characterization of Disease Hallmarks

Improve individual patient care


- Clinically proven detection and longitudinal quantitation for follow-up
- Moves imaging from diagnostics and staging to therapy assessment

Accelerate adoption of new molecular diagnostics

Make clinical trials of new therapies more effective

All tied to quantitative accuracy

The QIBA Profile Provides Guidance for all aspects of quantitative FDG-PET/CT



What we've done and how you can participate

- ✓ Collection of recommendations for quantitative FDG-PET
 - ✓ Presentation (joint with FNHI) to FDA
 - ✓ Year 1 research targets
 - ✓ Year 2 research targets
 - ✓ FDG-PET/CT Profile published and publically reviewed
 - ✓ Collaboration with UPICT on Protocols
 - Bi-weekly telephone conferences
 - Annual QIBA meetings and updates at RSNA
 - Working visits with vendors
 - Profile development
 - Year 3 research targets
 - Profile testing
 - Implementation of Profiles by QIBA and vendors
 - Clinical use of Profiles
- Completed**
- In progress**
- TBD**

More information at <http://rsna.org/QIBA.aspx>

QIBA FDG-PET/CT TC Projects: Completed

Title	PI
Meta-analysis to analyze the robustness of FDG SUV changes as a response marker, post and during systemic and multimodality therapy, for various types of solid extracerebral tumors.	O. Hoekstra, U of the Netherlands
QIBA FDG-PET/CT Digital Reference Object Project	P. Kinahan, U of Washington
Analysis of SARC 11 Trial PET Data by PERCIST with Linkage to Clinical Outcomes	R. Wahl, Johns Hopkins U.
Personnel Support for FDG-PET Profile Completion	E. Petreanu, PAQ
Evaluation of the Variability in Determination of Quantitative PET Parameters of Treatment Response Across Performance Sites and Readers	P. Kinahan, U of Washington
Evaluation of FDG-PET SUV Covariates, Metrics and Response Criteria	R. Wahl, Johns Hopkins U.
Integration of Retrospective Reviews of 2-3 Groupings of Clinical Trial Datasets (This includes the current Hoekstra proposal) Will utilize the PERCIST analysis	J. Yap, Dana Farber CI
FDG-PET/CT Publically Reviewed Profile	O. Hoekstra, U of the Netherlands
	QIBA FDG PET/CT Technical Committee

QIBA FDG-PET/CT TC Projects: Underway

Title	PI
FDG PET/CT Profile Field Test	T. Turkington, Duke University
	R. Boellaard, U of the Netherlands
	M. Lodge, Johns Hopkins University
QIBA FDG-PET/CT Digital Reference Object Project Extensions	P. Kinahan, University of Washington
Uniform Protocol for Imaging in Clinical Trials (UPICT) for FDG-PET/CT: Public Comment phase	J. Yap, University of Utah
Amyloid PET Neuroimaging Profile	TBD

Various QIBA projects and activities have been funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN268201000050C.